First, format flexibility six prescription compounds across four mechanism classes, including weekly injection, daily oral tablet, microdose troche/capsule/lozenge/sublingual, and dual-compound semaglutide-plus-tirzepatide stacks
Innovation Directions Rather than pursuing oral convenience, leading companies focus on injectable innovation: Extended-release formulations reducing injection frequency (monthly, quarterly) Multi-target mechanisms enhancing efficacy beyond single GLP-1 activation Combination therapies addressing multiple obesity pathways simultaneously Improved delivery devices enhancing patient experience with injections Amgens monthly MariTide exemplifies this approach, achieving 20% weight loss with just 12 annual injections versus 52 for weekly alternatives
Dont forget about your smile
Inhibition of Glucagon Release GLP-1 helps regulate blood sugar by inhibiting glucagon, a hormone that triggers the liver to release stored glucose, which can raise blood sugar levels
Goel reviews your labs and recommends the right infusion protocol not a generic menu pick